

ALTEX

ALTERNATIVES TO ANIMAL EXPERIMENTATION

Food for thought ...

Paul L. Carmichael et al.

**Ready for regulatory use:
NAMs and NGRA for chemical
safety assurance**

Research Article

Rebecca von Hellfeld et al.

**Zebrafish embryo neonicotinoid
developmental neurotoxicity
in the FET test and behavioral
assays**

Research Article

John S. House et al.

**Grouping of UVCB substances
with dose-response
transcriptomics data from
human cell-based assays**

Research Article

Patrícia Zoio et al.

**Open-source human
skin model with an *in vivo*-like
barrier for drug testing**

Concept Article

Giorgia Pallocca et al.


**Next-generation risk assessment
of chemicals – Rolling out a
human-centric testing strategy to
drive 3R implementation: The
RISK-HUNT3R project perspective**

Research Article

Arijit Bhattacharjee and

Dhirendra S. Katti

**A human osteoarthritis
mimicking goat cartilage
explant-based disease
model for drug screening**



Historical Article

Robert A. Baan and Kurt Straif

**The Monographs Programme
of the International
Agency for Research on
Cancer: A brief history
of its preamble**

Concept Article

Elisa Aiassa et al.

**EFSA's framework for
evidence-based scientific
assessments: A case
study on uncertainty analysis**

Review Article

Nawal Farhat et al.

**Systematic review
in evidence-based risk
assessment**

Research Article

Salomon Sand

**A novel method for combining
outcomes with different
severities or gene-level
classifications**

BenchMarks

Giorgia Pallocca and Marcel Leist

**On the usefulness of animals
as a model system (part II):
Considering benefits within
distinct use domains**

Meeting Reports

Corners





Dear readers,

In light of comments from DG Environment's Katrin Schütte at the recent ONE 2022 conference reported by *Chemical Watch*¹, which indicate that the European Commission considers that current "NAM [New approach methodology] methods today are not able to demonstrate adversity" and that therefore animal testing will have to increase to fulfill the Commission's chemicals strategy for sustainability (CSS), it is apt that this issue's Food for Thought ... contribution written by Paul Carmichael and colleagues from Unilever's Safety & Environmental Assurance Centre (SEAC) challenges the dogma that risk assessment must be built on predicting potential adversity (in rodents) and argues that protection of human health can already be achieved with NAM within next generation risk assessments (NGRA). This is complemented by the strategy paper of RISK-HUNT3R by Giorgia Pallocca et al., which outlines how this large Horizon 2020 project will assemble NAMs from computational toxicology, *in vitro* toxicology, and systems biology into NGRA strategies.

This theme is continued by the first four articles of our new *Special Issue* on Development of an Evidence-Based Risk Assessment², introduced by Thomas Hartung and Daniel Krewski. Robert Baan and Kurt Straif describe the evolution of the procedure by which the International Agency for Research on Cancer (IARC) Monographs Programme performs its evaluations, which now considers mechanistic evidence and exposure assessment methods, and integrates human data, experimental animal data, and mechanistic data from NAMs, thus potentially reducing or avoiding experimental animal use. Elisa Aiassa and colleagues present two building blocks of the European Food Safety Agency (EFSA)'s framework for evidence-based scientific assessments, i.e., how scientific assessments are conducted and how uncertainty analysis is performed, to enable integration of multiple evidence sources, including alternative methods and testing strategies, in the regulatory scientific assessment process. Nawal Farhat et al. explain how systematic reviews of existing human, animal and mechanistic data can reduce reliance on animals and help avoid duplication of animal experiments while helping to validate and implement alternative test methods. Salomon Sand presents an approach to combine data on multiple health or gene-level effects of chemicals or mixtures. This involves relating the dose or concentration used in an assay to standardized severity reference points such as benchmark doses. Working with such reference point profiles can support the combination of data from different data streams and the transition towards a NAM-based risk assessment paradigm.

Further main articles in this issue include the paper by Rebecca von Hellfeld et al., which assesses the effects of neo-

nicotinoids on embryonic development and behavior using the zebrafish embryo. They find that the embryo behavior outcomes correlate with findings in mammalian studies and that this assay could be integrated into a tiered testing scheme for (developmental) neurotoxicity testing.

UVCB substances, i.e., substances of unknown or variable composition, complex reaction products, and biological materials, such as petroleum substance extracts, pose special challenges for hazard and risk assessment. John House and colleagues extend their previous work on using *in vitro* assays to group UVCBs by investigating the use of transcriptomic profiling to support such grouping and provide mechanistic information.

While commercially available full skin models are highly standardized and convenient, they may be too expensive for some users, cannot be tailored to specific applications, and shipment to some countries may be problematic. Patrícia Zoio et al. assess the use of their open-source full thickness skin model as well as an open-source reconstructed human epidermis model for skin irritation testing.

Knee joints of goats from food production that are exposed to interleukin-1 β , a physiological inflammatory signal, display matrix degradation, expression of inflammatory and degradative markers, and chondrocyte hypertrophy that are comparable to human osteoarthritis patient samples and can be ameliorated with drugs commonly used to treat osteoarthritis. This *ex vivo* model, developed by Arijit Bhattacharjee and Dharendra Katti, could be used to screen for more effective drugs to halt or reverse disease progression.

How systematic review can be integrated with the evaluation of mechanistic evidence, especially with regard to the development of adverse outcome pathways (AOP), is the subject of a t4 Workshop Report by Sebastian Hoffmann and colleagues. Two further meeting reports and the Corners give insight into recent activities in the field. Finally, the BenchMarks contribution by Giorgia Pallocca and Marcel Leist continues to explore how to evaluate the usefulness of animal models by defining use domains.

Wishing you a good summer and a successful EUSAAT conference in September,

Sonja von Aulock
Editor-in-chief

¹ <https://chemicalwatch.com/513543/european-commission-increase-in-animal-testing-unavoidable-with-chemicals-strategy>

² doi:10.14573/altex.22S2

Subscribe to ALTEX

Support open access publication of 3Rs research



SUBSCRIPTION SERVICE

ALTEX Edition,
Romanshonerstrasse 90,
8280 Kreuzlingen, Switzerland
e-mail: subs@altex.org

First name

Last name

Institute/Library
(if applicable)

Address

State

Zip code

Country

e-mail

Date/signature

Please send completed form to the above address.

ALTEX (four issues):

☐ Individual subscription

102 €

☐ Library

204 €

(companies, institutes, libraries)

☐ Reduced

55 €

(students, animal protection organizations,
selected scientific societies)

Prices include postage for all countries.

The subscription is automatically renewed
unless it is cancelled by the end of the year.

I want to pay by

☐ credit card

☐ check

☐ electronic bank transfer

☐ please send me an invoice

ALTEX is available online:
<http://www.altex.org>

EUSAAT 2022

The European Congress on 3Rs

September 26 – 28
University of Linz, Austria

TOPICS

- Advancements in Replacement, Refinement & Reduction
- Emerging technologies (stem cells, microphysiological systems, spheroids/organoids, in silico approaches)
- Novel Approach Methodologies
- Non-animal methods
- 3Rs in education and academia
- 3Rs and policy
- 3Rs centres and platforms
- Covid-19 pandemic and 3Rs

HIGHLIGHTS

Young Scientists Travel Awards (YSTA)

A significant number of awards sponsored by SET are waiting for their awardees, the best YSTA lectures will receive additional prizes sponsored by ATLA.

YOU EVENT – Young Scientists in Action

Build your network, meet the experts and mentors

SUPPORT for Ukrainian Scientists

EUSAAT is sponsoring the participation of 3 scientists from the Ukraine in the EUSAAT 2022 Congress

The 2022 EUSAAT Congress is an in-person conference. Online attendance is not possible.

Register now on
www.eusaat.eu

CO-ORGANIZERS & SPONSORS

